Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Rantalaiho, V ^a   Puolakka, K ^b   Korpela, M ^a   Hannonen, P ^c   Mottonen T ^d  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Disease modifying anti rheumatic drug; FIN RACo trial; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; HUMAN; LONG TERM CARE; LONG TERM SURVIVAL; LOW DRUG DOSE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORK DISABILITY;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FINLAND; HUMANS; HYDROXYCHLOROQUINE; LONGITUDINAL STUDIES; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84870278198     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. LUUKKAINEN R, KAJANDER A, ISOMÄKI H: Effect of gold on progression of erosions in rheumatoid arthritis. Better results with early treatment. Scand J Rheumatol 1977;6:189-92.
2. WILSKE KR, HEALEY LA: Remodeling the pyramid-a concept whose time has come. J Rheumatol 1989;16:565-7.
3. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
4. MOTTONEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
5. KORPELA M, LAASONEN L, HANNONEN P et al.: Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying anti-rheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81.
6. LARSEN A, DALE K, EEK M: Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977;18:481-91.
7. PUOLAKKA K, KAUTIAINEN H, MÖTTÖNEN T ET AL.: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41.
8. PUOLAKKA K, KAUTIAINEN H, MÖTTÖNEN T ET AL.: Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50:55-62.
9. PUOLAKKA K, KAUTIAINEN H, PEKURINEN M et al.: Monetary value of lost productivity over a 5-year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo Trial. Ann Rheum Dis 2006;65:899-904.
10. RANTALAIHO V, KORPELA M, HANNONEN P et al.: The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time: The eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009;60:1222-31.
11. RANTALAIHO V, KORPELA M, LAASONEN L et al.: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010;12:R122.
12. MÖTTÖNEN T, HANNONEN P, KORPELA M et al.: Delay to institution of therapy and induction of remission using single-drug or combination-disease- modifying anti-rheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
13. MÄKINEN H, KAUTIAINEN H, HANNONEN P et al.: Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34:316-21.
14. OLSEN NJ, CALLAHAN LF, BROOKS RH et al.: Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. Am J Med 1988;84:257-64.
15. MUSTILA A, KORPELA M, HAAPALA AM et al.: Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol 2011;29:500-5.
16. NEVA MH, KAUPPI MJ, KAUTIAINEN H et al.: Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. Arthritis Rheum 2000;43:2397-401.
17. KAUPPI MJ, NEVA MH, LAIHO K et al.: Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs. J Rheumatol 2009;36:273-8.
18. KAARELA K, KAUTIAINEN H: Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol 1997;24:1285-7.
19. LINDQVIST E, JONSSON K, SAXNE T, EBERHARDT K: Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003;62:611-6.
20. TIIPPANA-KINNUNEN T, LAASONEN L, KAUTIAINEN H, PAIMELA L, LEIRISALO-REPO M: Impact of early radiographic remission on the 15-year radiographic outcome in patients with rheumatoid arthritis. Scand J Rheumatol 2011;40:263-8.
21. RANTALAI HO: The initial treatment strategy and the long-term outcome of early rheumatoid arthritis with special interest in the FIN-RACo trial and the current Finnish practice [Thesis]. Tampere, Finland, University of Tampere; 2012, 211
22. SMOLEN JS, ALETAHA D, BIJLSMA JW et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
23. DE JONG PH, HAZES JM, BARENDREGT PJ et al.: Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2012.
24. KIRWAN JR, BIJLSMA JW, BOERS M, SHEA BJ: Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007: CD006356.
25. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
26. GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
27. BARKER MF, JACOBS JW, WELSING PM et al.: Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med 2012;156:329-39.
28. LEIRISALO-REPO M, KAUTIAINEN H, LAASONEN L et al.: Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 2012.
29. VAN TUYL LH, LEMS WF, VOSKUYL AE et al.: Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574-7.
30. SAUNDERS SA, CAPELL HA, STIRLING A et al.: Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008;58:1310-7.
31. ALBERS JM, PAIMELA L, KURKI P et al.: Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:453-8.
32. SOKKA T, KAUTIAINEN H, TOLOZA S et al.: QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66:1491-6.
33. Rheumatoid arthritis (online). Current Care Guideline. Article in Finnish. Working group set up by the Finnish Medical Society Duodecim and the Finnish Society for Rheumatology. Helsinki: The Finnish Medical Society Duodecim, 2003 (retrieved August 13 2009). Available on internet: www.kaypahoito.fi 2009.
34. NEOVIUS M. SIMARD JF, ASKLING J: Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011;70:624-9.
35. RANTALAIHO V, KAUTIAINEN H, VIRTA L, KORPELA M, MÖTTÖNEN T, PUOLAKKA K: Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007. Scand J Rheumatol 2011;40:16-21.
36. ZIEGLER S, HUSCHER D, KARBERG K, KRAUSE A, WASSENBERG S, ZINK A: Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 2010;69:1803-8.
37. RANTALAIHO VM, KAUTIAINEN H, JARVENPAA S et al.: Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8. Ann Rheum Dis 2012.